http://www.arizonabiotech.com/
Enhanced understanding of genetic basis of disease to hasten advent of
personalized medicine

Phoenix, AZ – March 9, 2009 – Applied Biosystems, a division of Life
Technologies Corporation (NASDAQ: LIFE), and the Translational Genomics Research
Institute, today announced a strategic alliance designed to accelerate research
into complex diseases and medical conditions. As part of this alliance, a team
of scientists from TGen and Applied Biosystems will employ the SOLiD™ 3 System,
Applied Biosystems' next-generation genomic analysis platform, to sequence DNA
from thousands of patients with a variety of diseases. The goal of this research
is to translate scientific discoveries at the genetic level into knowledge about
the underlying causes of disease that may ultimately be used to create
cutting-edge tools for use in clinical diagnosis.

The alliance enables TGen researchers to apply best-of-breed sequencing
technology across a broad spectrum of research efforts that focus on developing
a more personalized approach to medicine. This approach, which is known as
personalized medicine, represents a potential clinical shift from treatment of
disease based on symptoms, to therapy that is specific to an individual's unique
genetic make up. Among the goals of this project is to advance the promise of
personalized medicine by reducing the cost of genome sequencing to make it a
routine diagnostic tool in medical care.

"This strategic alliance will accelerate genomic discoveries by integrating
relevant scientific findings into the clinical setting," said Mark Stevenson,
President and Chief Operating Officer of Life Technologies. "The SOLiD System
will help this team of scientists and other researchers and clinicians interpret
how genetic variation can improve the ability to create more effective
therapeutic solutions, bringing personalized medicine one step closer to
mainstream application."

The scientists involved in this alliance will utilize a total of five SOLiD 3
Systems to build a sequencing pipeline in connection with patient-centric,
medically-directed resequencing on a cross section of patient samples. The
results are expected to positively impact individuals with cancer, autoimmune
and neurological disorders. The alliance will also involve the co-development of
a bioinformatics analysis and visualization pipeline for the SOLiD platform.
This will result in software tools designed to ease the analytical challenges
associated with analyzing the vast amounts of data generated by human disease
and cancer genomics applications of next generation sequencing.

Dr. Jeffrey Trent, President and Scientific Director of TGen, and other renowned
principal investigators will partner with Applied Biosystems scientists to
perform six different projects focused on comprehensive characterization of
genetic and molecular changes occurring within clinical cohorts for each
disease. The scientists at TGen chose the SOLiD technology for this project, due
to its inherent scalability, unparalleled throughput and unmatched data
accuracy. These attributes make the SOLiD System uniquely suited for
translational research of complex diseases by enabling the detection of single
nucleotide polymorphisms and other structural variation across the genome in
large numbers of samples.

"Consistent with TGen's mission of developing the next generation of diagnostics
and therapeutics, the alliance with Applied Biosystems forges ties with a key
industry partner whose technologies align seamlessly with our research
objectives and should produce accelerated progress in our efforts to better
understand the genetic underpinnings of many diseases, with a particular
emphasis on cancer," said Dr. Trent.

Applied Biosystems is a global leader in providing innovative instrument systems
to accelerate academic and clinical research, drug discovery and development,
pathogen detection and forensic DNA analysis. The technologies it markets
include a robust line of DNA sequencing systems and chemistries to meet the
increasing demands of the scientific community for higher throughput, more
sophisticated DNA sequencing solutions. Applied Biosystems, together, with
Invitrogen – a leading provider of platform independent, essential life science
technologies for disease and drug research, bioproduction and diagnostics – is
part of Life Technologies Corporation, which markets the life science industry's
most comprehensive portfolio of solutions for molecular and cell biology.
Applied Biosystems and Invitrogen products are used in nearly every major
laboratory in the world.

TGen is a growing leader in integrating medically directed technologies and
applications into clinical practice, the results of which provide real solutions
for patients. Through its recent alliance with the Van Andel Research Institute
in Grand Rapids, Michigan, TGen and VARI now have a national outreach to patient
populations across multiple diseases. That alliance combines the groundbreaking
basic research expertise of VARI with the cutting-edge translational genomics
and analysis capabilities of TGen.

For more information, please visit: www.appliedbiosystems.com,
www.invitrogen.com and www.tgen.org

About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools
company dedicated to improving the human condition. Our systems, consumables and
services enable researchers to accelerate scientific exploration, driving to
discoveries and developments that make life even better. Life Technologies
customers do their work across the biological spectrum, working to advance
personalized medicine, regenerative science, molecular diagnostics, agricultural
and environmental research, and 21st century forensics. Life Technologies had
sales of more than $3 billion in 2008, employs approximately 9,500 people, has a
presence in more than 100 countries, and possesses a rapidly growing
intellectual property estate of approximately 3,600 patents and exclusive
licenses. Life Technologies was created by the combination of Invitrogen
Corporation and Applied Biosystems Inc. For more information on how we are
making a difference please visit our website: www.lifetechnologies.com

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit
organization dedicated to conducting groundbreaking research with life changing
results. Research at TGen is focused on helping patients with diseases such as
cancer, neurological disorders and diabetes. TGen is on the cutting edge of
translational research where investigators are able to unravel the genetic
components of common and complex diseases. Working with collaborators in the
scientific and medical communities, TGen believes it can make a substantial
contribution to the efficiency and effectiveness of the translational process.
For more information, visit: www.tgen.org